全球卒中治療研發管線分析：2026年第二季趨勢與臨床試驗

製藥和生物技術公司正在積極開發新型溶栓劑、神經保護劑、抗發炎療法、再生醫學和聯合治療，以滿足急性中風治療和長期康復方面尚未滿足的臨床需求。

中風仍然是全球死亡和長期殘疾的主要原因之一，而研發管線的重點主要集中在缺血性中風。儘管溶栓治療和機械取栓術已顯著改善了臨床療效，但仍有相當一部分患者不適合接受現有治療或遭受永久性神經病變。本管線分析全面深入探討了在臨床實驗療法、臨床開發階段、作用機制、申辦方活動、監管趨勢、競爭格局以及商業化機遇，這些因素將共同塑造未來中風治療的格局。

市場促進因素

全球中風負擔日益加重。

由於老化、高血壓、糖尿病、肥胖、心房顫動和其他心血管危險因子導致中風發病率不斷上升，對創新療法的需求也日益迫切。中風帶來的巨大醫療和經濟負擔，正推動藥物研發和臨床開發領域的持續投入。

下一代再灌注療法的擴展

臨床上對改善再灌注治療效果的日益關注，正在加速研發新一代溶栓藥物，這些藥物能夠簡化給藥方式、加速治療進程並擴大適用患者範圍。近期監管方面的進展也進一步加強了對該治療領域的投資。

人們越來越關注神經保護

製藥公司正在加強對神經保護療法的研究力度，旨在保護神經組織，並在缺血性損傷後促進長期功能恢復。這些療法是其研發管線中最具前景的創新領域之一。

影像導引治療的進展

神經影像技術的進步使得患者篩選更加精準，治療窗口期也得以延長。因此，臨床實驗試驗機構正積極研發與影像引導卒中管理策略相輔相成的療法。

區域趨勢

北美憑藉其先進的臨床研究基礎設施、強力的監管支持、廣泛的學術合作以及大量的製藥投資，仍然是中風治療藥物研發領域的主導地區。美國在藥物商業化和後期臨床開發方面繼續發揮主導作用。

歐洲憑藉其跨國臨床研究網路、完善的卒中治療體係以及積極參與全球藥物研發項目，保持強大的市場地位。影像引導治療策略也持續推動全部區域的創新發展。

受中國、日本、韓國、印度和澳洲中風盛行率上升、臨床試驗能力擴大、醫療保健基礎設施改善以及製藥投資增加等因素的推動，亞太地區有望成為中風治療發展領域成長最快的地區之一。

拉丁美洲、中東和非洲正透過醫療保健現代化、擴大中風治療能力以及加強與國際製藥公司的合作，逐步增加其參與跨國臨床研究的程度。

本報告調查了全球中風治療研發管線，總結了該管線的現狀、管線資產的分佈情況，並按研發階段、中風類型和藥物類型等各種類別進行了詳細分析，還按地區/主要國家進行了分析，介紹了競爭格局和主要公司的概況。

目錄

第1章執行摘要

第2章：管道概覽

• 中風藥物研發現狀
• 管道發展演變及歷史趨勢
• 管道資產分佈：依開發階段分類
  • 臨床前資產
  • 第一階段資產
  • 二期資產
  • 第三期資產
  • 已提交/審核中
• 管道資產分佈：按筆畫類型
  • 缺血性中風
  • 出血性中風
  • 急性中風
  • 二級預防中風
  • 中風後的恢復與神經保護
• 管道資產分佈：依發起人類型
  • 大型製藥公司
  • 生技公司
  • 學術和研究機構
• 管道成熟度評估
• 新發展領域

第3章：疾病分析及未滿足的需求

• 疾病概述
• 疾病負擔和流行病學
• 目前的標準治療
• 治療缺口和局限性
• 未滿足的臨床需求
• 未來治療需求
• 市場機會評估

第4章 作用機轉與作用方式

• 作用機轉概述
• 根據作用機理對管道進行分類
  • 溶栓治療
  • 抗血栓藥物
  • 神經保護療法
  • 抗發炎治療
  • 再生和修復機制
  • 血管保護策略
  • 一種基於新機制的方法
• 同類同類最佳First-in-Class的比較與評價
• 已確立的作用機制和新的作用機制
• 基於模態的分析
  • 小分子藥物
  • 生物製藥
  • 細胞療法
  • 基因治療
  • RNA療法
  • 聯合治療
• 創新強度圖譜
• 作用機轉層面的競爭性標竿分析

第5章 臨床開發智慧

• 臨床研究發現狀
• 臨床試驗活動的趨勢
• 臨床試驗設計基準測試
• 受試者招募與登記分析
• 臨床成功與失敗的趨勢
• 對以往開發案取消和退出情況的分析
• 主要發展挑戰
• 影響發展的監管因素
• 臨床開發最佳實踐

第6章：全球卒中治療產品線：細分市場分析

• 按發展階段
  • 臨床前開發平臺
  • 第一階段管道
  • 二期管道
  • 三期管道
  • 已提交/審核中管道
• 按類型描邊
  • 缺血性中風
  • 出血性中風
  • 短暫性腦缺血發作（TIA）
  • 其他
• 依藥物類型
  • 溶栓藥物
  • 抗血小板藥物
  • 抗凝血劑
  • 其他
• 治療類型
  • 靜脈注射
  • 血管內治療
  • 外科手術

第7章：成功機率與風險分析

• 風險評估框架
• 過去開發成功率
• 相變機率分析
• 資產層面成功機率建模
• 透過作用機制評估成功機率
• 贊助商成功率比較
• 開發取消/退出風險分析
• 臨床危險因子
• 監理風險因素
• 商業化風險因素
• 風險調整後的管道評估
• 成功機率加權銷售預測

第8章 市場上市時機/商業性可能性

• 核准時間預測評估
• 預測發布日期
• 與競品進行上市順序分析
• 市場進入分析
• 銷售高峰期的潛在評估
• 商機預測
• 市場滲透率預測
• 商業化風險分析
• 未來市場情境分析

第9章：競爭性管道情勢

• 競爭環境概述
• 管道強度評估：按公司
• 主要開發商排名
• 對新興挑戰者的分析
• 按發起人分類的資產集中度
• 依作用機轉進行所有權分析
• 創新領導力評估
• 戰略定位矩陣
• 競爭基準分析儀錶板
• 未來競爭力展望

第10章 區域分析

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲

第11章 主要國家分析

• 加拿大
• 德國
• 中國
• 日本
• 印度

第12章：交易與投資展望

• 授權協議
• 聯合發展夥伴關係
• 研究合作
• 策略聯盟
• 併購活動
• 創業投資
• 私募股權資金籌措
• 公開市場融資
• 交易價值趨勢
• 投資熱點
• 未來夥伴關係展望

第13章：未來展望與策略洞察

• Genentech
• Boehringer Ingelheim
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Bayer AG
• Johnson & Johnson
• Daiichi Sankyo
• Sanofi
• Novo Nordisk
• AstraZeneca PLC
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• AbbVie Inc.
• 未來競爭格局
• 新的創新主題
• 策略建議
• 長期市場展望

第14章：調查方法與資料框架

Pharmaceutical and biotechnology companies are actively advancing novel thrombolytics, neuroprotective agents, anti-inflammatory therapies, regenerative medicines, and combination approaches to address the significant unmet clinical needs in acute stroke management and long-term recovery.

Stroke remains one of the leading causes of death and long-term disability worldwide, with ischemic stroke representing the primary focus of pipeline development. Although thrombolysis and mechanical thrombectomy have significantly improved clinical outcomes, many patients remain ineligible for current interventions or continue to experience permanent neurological impairment. Drug pipeline analysis provides comprehensive insights into investigational therapies, clinical development stages, mechanisms of action, sponsor activities, regulatory trends, competitive positioning, and commercialization opportunities that are shaping the future stroke treatment landscape.

Market Drivers

Growing Global Stroke Burden

The increasing incidence of stroke resulting from aging populations, hypertension, diabetes, obesity, atrial fibrillation, and other cardiovascular risk factors continues to accelerate demand for innovative therapeutic options. The substantial healthcare and economic burden associated with stroke is encouraging sustained investment in drug discovery and clinical development.

Expansion of Next-Generation Reperfusion Therapies

Growing clinical interest in improving reperfusion outcomes has accelerated development of next-generation thrombolytic agents that offer simplified administration, faster treatment, and broader patient eligibility. Recent regulatory advances have further strengthened investment in this therapeutic area.

Increasing Focus on Neuroprotection

Pharmaceutical companies are expanding research into neuroprotective therapies designed to preserve neuronal tissue during ischemic injury and improve long-term functional recovery. These therapies represent one of the most promising areas of pipeline innovation.

Advances in Imaging-Guided Treatment

Improved neuroimaging technologies are enabling more precise patient selection and extending treatment windows, encouraging sponsors to develop therapies that complement imaging-guided stroke management strategies.

Market Restraints

High Clinical Failure Rates

Neuroprotective drug development has historically experienced high attrition rates because of complex stroke biology, heterogeneous patient populations, and difficulties in demonstrating consistent clinical benefit.

Complex Clinical Development

Stroke drug development requires rapid patient enrollment, standardized imaging protocols, large multicenter studies, and long-term neurological outcome assessment, making clinical trials expensive and operationally demanding.

Regulatory Challenges

Regulatory agencies require robust evidence demonstrating meaningful improvements in functional recovery while maintaining acceptable safety profiles, particularly regarding bleeding risk associated with reperfusion therapies.

Pipeline and Technology Insights

The global stroke drug pipeline can be segmented by development phase, stroke type, drug type, treatment type, mechanism of action, and geography.

By development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed/under regulatory review candidates. Phase II and Phase III programs represent the largest share of active development as sponsors advance promising therapies toward commercialization.

By stroke type, pipeline activity covers ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke dominates development because it represents the majority of stroke cases and offers the greatest opportunity for therapeutic innovation.

By drug type, the pipeline includes thrombolytics, antiplatelets, anticoagulants, neuroprotective agents, anti-inflammatory therapies, regenerative therapies, and other investigational drug classes. Thrombolytics remain the most active development category, while neuroprotective and regenerative therapies continue to expand as sponsors pursue complementary treatment approaches.

By treatment type, pipeline assets include intravenous medications, endovascular therapies, and surgical procedures, including mechanical thrombectomy and carotid endarterectomy. Drug developers increasingly seek therapies that complement existing interventional procedures and improve functional outcomes.

Technological innovation continues to support pipeline advancement through artificial intelligence-assisted imaging, biomarker-guided patient selection, precision medicine, adaptive clinical trial designs, and digital health platforms that improve trial efficiency and treatment optimization.

Pipeline Trends

The global stroke drug pipeline continues to evolve toward targeted and combination therapeutic strategies.

Key trends include:

• Expansion of next-generation thrombolytic development.
• Increasing investment in neuroprotective therapies.
• Growing development of combination therapies with thrombectomy.
• Broader use of imaging-guided patient selection.
• Expansion of regenerative medicine and neurological recovery programs.
• Increasing adoption of adaptive clinical trial designs.
• Greater focus on extending treatment eligibility windows.

Regional Insights

North America remains the leading region for stroke drug pipeline development because of advanced clinical research infrastructure, strong regulatory support, extensive academic collaboration, and substantial pharmaceutical investment. The United States continues to lead commercialization and late-stage clinical development.

Europe maintains a strong position through multinational clinical research networks, established stroke care systems, and active participation in global drug development programs. Imaging-guided treatment strategies continue to drive innovation across the region.

Asia-Pacific is expected to emerge as one of the fastest-growing regions for stroke drug development owing to increasing stroke prevalence, expanding clinical trial capabilities, improving healthcare infrastructure, and growing pharmaceutical investment across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening their participation in multinational clinical research through healthcare modernization, expanding stroke treatment capacity, and increasing collaboration with international pharmaceutical companies.

Competitive Landscape

The global stroke drug pipeline includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, and emerging biotechnology developers.

Leading organizations continue investing in next-generation thrombolytics, neuroprotective agents, regenerative medicine, anti-inflammatory therapies, precision medicine, and combination treatment strategies. Strategic licensing agreements, collaborative research partnerships, mergers and acquisitions, and regulatory acceleration programs remain central to competitive growth. Companies including Genentech, Boehringer Ingelheim, Roche, Novartis, Bayer, Johnson & Johnson, Daiichi Sankyo, and Sanofi are actively strengthening their stroke development portfolios.

Future Outlook

The future of the stroke drug pipeline will be shaped by continued advances in precision neurology, artificial intelligence, regenerative medicine, imaging-guided treatment, and personalized therapeutics. Expansion of neuroprotective strategies, improved understanding of stroke pathophysiology, and broader integration of digital health technologies are expected to accelerate development of innovative therapies.

Increasing adoption of adaptive trial designs, biomarker-guided development, and combination treatment approaches will improve development efficiency while creating new commercial opportunities through 2035.

Conclusion

The global Stroke Drug Pipeline Analysis highlights a rapidly expanding development landscape supported by growing neurological research investment, innovation in thrombolytic therapies, advances in neuroprotection, and increasing emphasis on improving long-term functional recovery. Although challenges related to clinical complexity, regulatory requirements, and historical failure rates remain, continued advances in precision medicine, imaging technologies, and combination therapeutic strategies are expected to accelerate innovation and strengthen future commercialization opportunities.

Key Benefits of this Report

• Comprehensive analysis of the global stroke drug pipeline across all stages of development.
• Detailed evaluation of investigational therapies, mechanisms of action, and pipeline maturity.
• Competitive assessment of sponsor activities, strategic collaborations, and licensing trends.
• Insights into regulatory developments, emerging technologies, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, contract research organizations, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Pipeline benchmarking, portfolio optimization, competitive intelligence, licensing and partnership evaluation, clinical development planning, investment analysis, regulatory strategy development, commercialization planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke drug pipeline by development phase, stroke type, drug type, treatment type, and geography
• Evaluation of pipeline assets, clinical development progress, mechanisms of action, sponsor landscape, regulatory pathways, and commercialization potential
• Assessment of strategic collaborations, licensing agreements, mergers and acquisitions, competitive positioning, and emerging therapeutic innovations
• Analysis of thrombolytics, neuroprotective therapies, regenerative medicine, antiplatelets, anticoagulants, combination therapies, and future pipeline opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Stroke Drug Pipeline Snapshot
• 1.3 Key Pipeline Highlights
• 1.4 Clinical Development Trends
• 1.5 Innovation Landscape Overview
• 1.6 Competitive Intelligence Summary
• 1.7 Probability-Adjusted Opportunity Assessment
• 1.8 Key Strategic Takeaways

2. Pipeline Overview

• 2.1 Stroke Therapeutics Development Landscape
• 2.2 Pipeline Evolution and Historical Trends
• 2.3 Pipeline Asset Distribution by Development Stage
  • 2.3.1 Preclinical Assets
  • 2.3.2 Phase I Assets
  • 2.3.3 Phase II Assets
  • 2.3.4 Phase III Assets
  • 2.3.5 Filed / Under Regulatory Review Assets
• 2.4 Pipeline Asset Distribution by Stroke Type
  • 2.4.1 Ischemic Stroke
  • 2.4.2 Hemorrhagic Stroke
  • 2.4.3 Acute Stroke
  • 2.4.4 Secondary Stroke Prevention
  • 2.4.5 Post-Stroke Recovery and Neuroprotection
• 2.5 Pipeline Asset Distribution by Sponsor Type
  • 2.5.1 Large Pharmaceutical Companies
  • 2.5.2 Biotechnology Companies
  • 2.5.3 Academic and Research Institutions
• 2.6 Pipeline Maturity Assessment
• 2.7 Emerging Development Areas

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
• 3.2 Disease Burden and Epidemiology
• 3.3 Current Standard of Care
• 3.4 Treatment Gaps and Limitations
• 3.5 Unmet Clinical Needs
  • 3.5.1 Acute Intervention Challenges
  • 3.5.2 Neuroprotection Gaps
  • 3.5.3 Long-Term Recovery Limitations
  • 3.5.4 Secondary Prevention Challenges
• 3.6 Future Therapeutic Requirements
• 3.7 Market Opportunity Assessment

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Overview
• 4.2 Mechanism-Based Pipeline Clustering
  • 4.2.1 Thrombolytic Therapies
  • 4.2.2 Antithrombotic Agents
  • 4.2.3 Neuroprotective Therapies
  • 4.2.4 Anti-Inflammatory Therapies
  • 4.2.5 Regenerative and Repair Mechanisms
  • 4.2.6 Vascular Protection Strategies
  • 4.2.7 Novel Mechanistic Approaches
• 4.3 First-in-Class versus Best-in-Class Assessment
• 4.4 Established versus Emerging Mechanisms
• 4.5 Modality-Based Analysis
  • 4.5.1 Small Molecules
  • 4.5.2 Biologics
  • 4.5.3 Cell Therapies
  • 4.5.4 Gene Therapies
  • 4.5.5 RNA-Based Therapeutics
  • 4.5.6 Combination Therapies
• 4.6 Innovation Intensity Mapping
• 4.7 Mechanism-Level Competitive Benchmarking

5. Clinical Development Intelligence

• 5.1 Clinical Development Landscape
• 5.2 Clinical Trial Activity Trends
• 5.3 Trial Design Benchmarking
  • 5.3.1 Study Design Analysis
  • 5.3.2 Sample Size Assessment
  • 5.3.3 Endpoint Benchmarking
  • 5.3.4 Duration Analysis
  • 5.3.5 Patient Selection Criteria
• 5.4 Recruitment and Enrollment Intelligence
• 5.5 Clinical Success and Failure Trends
• 5.6 Historical Attrition Analysis
• 5.7 Key Development Challenges
• 5.8 Regulatory Considerations Impacting Development
• 5.9 Clinical Development Best Practices

6. Global Stroke Drug Pipeline Report Segmentation Analysis

• 6.1 By Development Phase
  • 6.1.1 Preclinical Pipeline
  • 6.1.2 Phase I
  • 6.1.3 Phase II Pipeline
  • 6.1.4 Phase III Pipeline
  • 6.1.5 Filed / Under Review Pipeline
• 6.2 By Stroke Type
  • 6.2.1 Ischemic Stroke
    • 6.2.1.1. Thrombotic
    • 6.2.1.2. Embolic
  • 6.2.2 Hemorrhagic Stroke
  • 6.2.3 Transient Ischemic Attack
  • 6.2.4 Others
• 6.3 By Drug Type
  • 6.3.1 Thrombolytics
  • 6.3.2 Antiplatelets
  • 6.3.3 Anticoagulants
  • 6.3.4 Others
• 6.4. By Treatment Type
  • 6.4.1.IV Medication
  • 6.4.2. Endovascular Therapy
  • 6.4.3. Surgical Procedures
    • 6.4.3.1. Mechanical Thrombectomy
    • 6.4.3.2. Carotid Endarterectomy (CEA)
    • 6.4.3.3. Others

7. Probability of Success and Risk Analysis

• 7.1 Risk Assessment Framework
• 7.2 Historical Development Success Rates
• 7.3 Phase Transition Probability Analysis
  • 7.3.1 Preclinical to Phase I
  • 7.3.2 Phase I to Phase II
  • 7.3.3 Phase II to Phase III
  • 7.3.4 Phase III to Approval
• 7.4 Asset-Level Probability of Success Modeling
• 7.5 Mechanism-Level Success Probability Assessment
• 7.6 Sponsor-Level Success Benchmarking
• 7.7 Attrition Risk Analysis
• 7.8 Clinical Risk Factors
• 7.9 Regulatory Risk Factors
• 7.10 Commercial Risk Factors
• 7.11 Risk-Adjusted Pipeline Valuation
• 7.12 Probability-Weighted Revenue Forecasting

8. Launch Timeline and Commercial Potential

• 8.1 Expected Approval Timeline Assessment
• 8.2 Launch Window Forecasting
• 8.3 Competitive Launch Sequencing
• 8.4 Market Entry Analysis
• 8.5 Peak Sales Potential Assessment
• 8.6 Revenue Opportunity Forecast
• 8.7 Market Penetration Expectations
• 8.8 Commercialization Risk Analysis
• 8.9 Future Market Scenario Modeling

9. Competitive Pipeline Landscape

• 9.1 Competitive Environment Overview
• 9.2 Company-Wise Pipeline Strength Assessment
• 9.3 Leading Developers Ranking
• 9.4 Emerging Challenger Analysis
• 9.5 Asset Concentration by Sponsor
• 9.6 Mechanism Ownership Analysis
• 9.7 Innovation Leadership Assessment
• 9.8 Strategic Positioning Matrix
• 9.9 Competitive Benchmarking Dashboard
• 9.10 Future Competitive Outlook

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
  • 10.1.4 Key Development Sponsors
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
  • 10.2.4 Key Development Sponsors
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
  • 10.3.4 Key Development Sponsors
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
  • 10.4.4 Key Development Sponsors
• 10.5 Middle East and Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem
  • 10.5.4 Key Development Sponsors

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Agreements
• 12.2 Co-Development Partnerships
• 12.3 Research Collaborations
• 12.4 Strategic Alliances
• 12.5 Merger and Acquisition Activity
• 12.6 Venture Capital Investments
• 12.7 Private Equity Funding
• 12.8 Public Market Financing
• 12.9 Deal Value Trends
• 12.10 Investment Hotspots
• 12.11 Future Partnership Outlook

13. Future Outlook and Strategic Insights

• 13.1 Genentech
  • 13.1.1 Pipeline Positioning
  • 13.1.2 Strategic Priorities
  • 13.1.3 Future Growth Outlook
• 13.2 Boehringer Ingelheim
  • 13.2.1 Pipeline Positioning
  • 13.2.2 Strategic Priorities
  • 13.2.3 Future Growth Outlook
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 Pipeline Positioning
  • 13.3.2 Strategic Priorities
  • 13.3.3 Future Growth Outlook
• 13.4 Novartis AG
  • 13.4.1 Pipeline Positioning
  • 13.4.2 Strategic Priorities
  • 13.4.3 Future Growth Outlook
• 13.5 Bayer AG
  • 13.5.1 Pipeline Positioning
  • 13.5.2 Strategic Priorities
  • 13.5.3 Future Growth Outlook
• 13.6 Johnson & Johnson
  • 13.6.1 Pipeline Positioning
  • 13.6.2 Strategic Priorities
  • 13.6.3 Future Growth Outlook
• 13.7 Daiichi Sankyo
  • 13.7.1 Pipeline Positioning
  • 13.7.2 Strategic Priorities
  • 13.7.3 Future Growth Outlook
• 13.8 Sanofi
  • 13.8.1 Pipeline Positioning
  • 13.8.2 Strategic Priorities
  • 13.8.3 Future Growth Outlook
• 13.9 Novo Nordisk
  • 13.9.1 Pipeline Positioning
  • 13.9.2 Strategic Priorities
  • 13.9.3 Future Growth Outlook
• 13.10 AstraZeneca PLC
  • 13.10.1 Pipeline Positioning
  • 13.10.2 Strategic Priorities
  • 13.10.3 Future Growth Outlook
• 13.11 Merck & Co., Inc.
  • 13.11.1 Pipeline Positioning
  • 13.11.2 Strategic Priorities
  • 13.11.3 Future Growth Outlook
• 13.12 GlaxoSmithKline plc
  • 13.12.1 Pipeline Positioning
  • 13.12.2 Strategic Priorities
  • 13.12.3 Future Growth Outlook
• 13.13 Eli Lilly and Company
  • 13.13.1 Pipeline Positioning
  • 13.13.2 Strategic Priorities
  • 13.13.3 Future Growth Outlook
• 13.14 AbbVie Inc.
  • 13.14.1 Pipeline Positioning
  • 13.14.2 Strategic Priorities
  • 13.14.3 Future Growth Outlook
• 13.15 Future Competitive Scenarios
• 13.16 Emerging Innovation Themes
• 13.17 Strategic Recommendations
• 13.18 Long-Term Market Outlook (2026-2035)

14. Methodology and Data Framework

• 14.1 Research Methodology
• 14.2 Data Sources and Validation Framework
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Information System (CTIS)
  • 14.2.3 Company Pipeline Disclosures
  • 14.2.4 Regulatory Filings
  • 14.2.5 Investor Presentations
• 14.3 Asset Inclusion Criteria
• 14.4 Pipeline Classification Methodology
• 14.5 Mechanism Classification Framework
• 14.6 Probability Modeling Methodology
• 14.7 Commercial Forecasting Methodology
• 14.8 Risk Adjustment Methodology
• 14.9 Competitive Intelligence Framework
• 14.10 Data Quality Assurance Process
• 14.11 Assumptions and Limitations
• 14.12 Abbreviations and Definitions
• 14.13 Appendix: Verifiable Asset Database Structure
• 14.14 Appendix: Clinical Trial Tracking Framework
• 14.15 Appendix: Sponsor Benchmarking Framework